Your knowledge of hepatitis serology. Hep B reactivation during immunosuppressive systemic cancer therapy is real among those with previous infection (as detected via the presence of core antibodies, anti-HBc), adding intrigue to this cohort study reporting a 6.5% incidence of anti-HBc among all cancer patients. | Ramsey, JAMA Oncol 2019


Popular Posts